Today’s cyclodextrin:
In the CD-world, CD-API conjugates received some attention, one candidate even reached clinics, yet most certainly, the true potential as an NCE or prodrug has not been explored.
Here is some encouragement, a case study on 5-flurouracil when tagged with BCD.
The results?
– superior antitumor activity
– reduced cytotoxicity towards normal cells
– slower elimination
– longer half-life
